Traws Pharma Inc (NASDAQ:TRAW)’s traded shares stood at 57254.0 during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $1.45, to imply a decrease of -0.68% or -$0.01 in intraday trading. The TRAW share’s 52-week high remains $19.44, putting it -1240.69% down since that peak but still an impressive 33.1% since price per share fell to its 52-week low of $0.97. The company has a valuation of $8.06M, with an average of 0.12 million shares in intraday trading volume over the past 10 days and average of 1.19 million shares over the past 3 months.

Traws Pharma Inc (NASDAQ:TRAW) trade information

After registering a -0.68% downside in the last session, Traws Pharma Inc (TRAW) has traded red over the past five days. The 5-day price performance for the stock is 1.40%, and -22.46% over 30 days. With these gigs, the year-to-date price performance is -86.54%. Short interest in Traws Pharma Inc (NASDAQ:TRAW) saw shorts transact 0.36 million shares and set a 0.12 days time to cover.

TRAW Dividends

Traws Pharma Inc has its next earnings report out on 2025-Mar-31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Traws Pharma Inc (NASDAQ:TRAW)’s Major holders

Traws Pharma Inc insiders hold 18.86% of total outstanding shares, with institutional holders owning 31.23% of the shares at 38.48% float percentage. In total, 31.23% institutions holds shares in the company.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Traws Pharma Inc (TRAW) shares. Going by data provided on Apr 30, 2025, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 16.85 shares. This is just over 0.30% of the total shares, with a market valuation of $24432.0. Data from the same date shows that the other fund manager holds a little less at 12.91, or 0.23% of the shares, all valued at about 18720.0.